Novartis AG (JOBS) to Combine Heart Pills as Afinitor Cancer Drug Delayed

November 19, 2008 |

1 min read

Bloomberg-- Novartis AG is betting on a clutch of combination heart pills to replace revenue from its best-selling hypertension drug Diovan, after its most-promising cancer treatment was delayed by three months.

Regulatory Europe

Novartis

MORE ON THIS TOPIC

Hand Marking Calendar Reminder Illustration. A professional hand uses a pen to circle a date on a red and white calendar, representing schedule planning and important reminders

FDA

Capricor’s Duchenne therapy has new life after FDA grants 3-month extension

August 24, 2026

·

2 min read

·

Heather McKenzie

Row of Falling Domino Stones Stopped by Red Domino Stone Over Black Background, Risk Management, Intervene or Prevention Concept, 3d Rendering

FDA

REGENXBIO’s Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans

August 24, 2026

·

2 min read

·

Heather McKenzie

Vaccines

Kennedy questions vaccination guidelines following Trump’s order to break up MMR

August 24, 2026

·

2 min read

·

Tristan Manalac

Businessmans hand holding a red globe with the map of China, symbolizing international business, trade, global markets, global influence, economics, or Chinese business ventures

Policy

Lawmakers urge FDA to enact new China policies after 3 gene therapy trial deaths

August 21, 2026

·

4 min read

·

Gabrielle Masson